Table 8.
Results Of The Cost-Effectiveness And Cost-Utility Analyses. Base Case
| Midostaurin + Chemotherapy | Chemotherapy | Incremental | |
|---|---|---|---|
| Cost | |||
| Pharmacological cost | € 61,250 | € 1,798 | € 59,452 |
| Induction | € 7,973 | € 466 | € 7,507 |
| Consolidation | € 12,881 | € 744 | € 12,138 |
| Maintenance | € 39,870 | € 0 | € 39,870 |
| 2nd line therapy | € 527 | € 589 | € −62 |
|
Cost of healthcare resources (non-pharmacological) |
€ 106,798 | € 121,374 | € −14,576 |
| During treatment | € 66,568 | € 60,439 | € 6,129 |
| After treatment | € 40,230 | € 60,935 | € −20,705 |
| HSCT costs | € 34,723 | € 31,315 | € 3,409 |
| Costs of mortality | € 5,082 | € 5,413 | € −331 |
| TOTAL COST | € 207,854 | € 159,900 | € 47,955 |
| Effectiveness | |||
| LYG | 11.73 | 10.27 | 1.46 |
| QALYs | 9.45 | 8.22 | 1.23 |
| ICER (€ per LYG): | € 32,854 | ||
| ICUR (€ per QALY gained): | € 38,985 | ||
Note: The values that are not in bold are components of the items in bold.
Abbreviations: QALY, Quality Adjusted Life Year; LYG, Life year gained; ICER, Incremental Cost Effectiveness Ratio; ICUR, Incremental Cost Utility Ratio.